Magnetic resonance imaging-ultrasound fusion-targeted biopsy combined with systematic 12-core ultrasound-guided biopsy improves the detection of clinically significant prostate cancer: Are we ready to abandon the systematic approach?

Journal: Urology annals
Published Date: Oct 15, 2020

Abstract

BACKGROUND: Multiparametric (mp) magnetic resonance imaging (MRI)-ultrasound fusion-targeted biopsy (TB) has improved the detection of clinically significant prostate cancer (csCaP) using the Prostate Imaging Reporting and Data System (PI-RADS) reporting system, leading some authors to conclude that TB can replace the 12-core systematic biopsy (SB). We compared the diagnostic performance of TB with SB at our institution.

Authors

  • Christopher Antonio Febres-Aldana
    Arkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Florida, USA.
  • Sarah Alghamdi
    Arkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Florida, USA.
  • Thomas A Weppelmann
    Department of Pathology, Herbert Wertheim College of Medicine, Florida International University, Florida, USA.
  • Emilio Lastarria
    Columbia University Division of Urology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
  • Akshay Bhandari
    Columbia University Division of Urology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
  • Yumna Omarzai
    Arkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Florida, USA.
  • Robert J Poppiti
    Arkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Florida, USA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals